Viral evasion of IFN function by decoy receptor sequestration

病毒通过诱饵受体隔离来逃避干扰素功能

基本信息

  • 批准号:
    8234940
  • 负责人:
  • 金额:
    $ 32.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-03-01 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

Interferon (IFN) activity is marshaled early against the initial stages of viral infection, and IFN mediated responses play an essential role in host defense by directly inhibiting viral replication and by indirectly stimulating innate and adaptive immunity. Not surprisingly, IFN mediated signaling is a favored target of viral subterfuge. In this proposal we set out to explore the biophysical and functional attributes of two virally encoded decoy receptors that selectively neutralize the biological effects of type-l and type-Ill IFNs. Ectromelia virus encodes a decoy receptor that promiscuously binds and blocks the antiviral effects of all type-l IFNs in a species independent manner, with the notable exception of murine IFN-beta. The Yaba-like disease virus encodes a related decoy receptor that capably inhibits primate type-l (alpha and beta) as well as type-Ill (lamda) IFNs. Interestingly, neither of these viral proteins shares any significant sequence similarity with the distinct receptor components used for type-l or type-Ill IFN signal transduction. Our proposed studies aim to dissect the mechanism and consequences of selective decoy receptor mediated IFN inhibition using a diverse arsenal of experimental methods. In Aim 1 of the proposal we will determine the structural basis of IFN inhibition by viral decoy receptors using x-ray crystallography and quantitative protein interaction analysis. Results from these studies will be used in concert with yeast surface display directed evolution to develop variant decoy receptors with unique cytokine binding properties. In Aim 2 we will examine the cellular mechanisms of IFN decoy receptor function. The secreted poxvirus proteins tightly associate with cell surfaces through an unknown receptor interaction we propose to identify and investigate. We will also examine whether additional viruses encode IFN decoys. In Aim 3 we will explore the role of IFN sequestration in the mousepox pathogenesis model. Ectromelia recombinants will be generated that encode novel decoy receptors that selectively inhibit the actions of IFN-alpha, IFN-beta, or IFN-lambda at sites of viral infection in order to better understand the specific roles of these cytokines in anti-viral immunity.
干扰素(IFN)活性在病毒感染的初始阶段就被排列起来,IFN介导 应答通过直接抑制病毒复制和间接抑制病毒复制, 刺激先天性和适应性免疫。毫不奇怪,IFN介导的信号传导是病毒感染的有利靶点。 托词在这项提议中,我们着手探索两种病毒的生物物理和功能属性, 编码诱饵受体,选择性地中和I型和III型IFN的生物效应。 鼠痘病毒编码一个诱饵受体,混杂地结合并阻断所有的抗病毒作用。 I型IFN以物种独立的方式表达,鼠IFN-β是显著的例外。Yaba类 疾病病毒编码一种相关的诱饵受体,该受体也能抑制灵长类动物的I型(α和β) 作为III型(λ)IFN。有趣的是,这些病毒蛋白质都没有任何重要的序列 与用于I型或III型IFN信号转导的不同受体组分相似。我们 提出的研究旨在剖析选择性诱饵受体介导的 使用不同的实验方法抑制IFN。在提案的目标1中,我们将确定 用X射线晶体学和定量分析病毒诱饵受体抑制IFN的结构基础 蛋白质相互作用分析这些研究的结果将与酵母表面展示一起使用 定向进化以开发具有独特细胞因子结合特性的变体诱饵受体。在目标2中, 将研究干扰素诱饵受体功能的细胞机制。痘病毒分泌的蛋白质 与细胞表面通过未知的受体相互作用,我们建议确定和调查。 我们还将研究是否有其他病毒编码干扰素诱饵。在目标3中,我们将探讨IFN的作用, 隔离的小鼠痘发病模型。将产生编码 选择性地抑制IFN-α、IFN-β或IFN-λ作用的新诱饵受体, 病毒感染,以便更好地了解这些细胞因子在抗病毒免疫中的具体作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daved H. Fremont其他文献

Structural basis for plasticity in receptor engagement by an encephalitic alphavirus
一种致脑炎甲病毒受体结合可塑性的结构基础
  • DOI:
    10.1016/j.cell.2025.02.036
  • 发表时间:
    2025-05-29
  • 期刊:
  • 影响因子:
    42.500
  • 作者:
    Saravanan Raju;Sathvik Palakurty;Alan Sariol;Ngan Wagoner;Lucas J. Adams;Sean Hui;William B. Klimstra;Daved H. Fremont;Michael S. Diamond
  • 通讯作者:
    Michael S. Diamond
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
  • DOI:
    10.1016/j.chom.2024.10.016
  • 发表时间:
    2024-12-11
  • 期刊:
  • 影响因子:
  • 作者:
    James Brett Case;Shilpa Sanapala;Carly Dillen;Victoria Rhodes;Christian Zmasek;Taras M. Chicz;Charlotte E. Switzer;Suzanne M. Scheaffer;George Georgiev;Catherine Jacob-Dolan;Blake M. Hauser;Déborah Carolina Carvalho Dos Anjos;Lucas J. Adams;Nadia Soudani;Chieh-Yu Liang;Baoling Ying;Ryan P. McNamara;Richard H. Scheuermann;Adrianus C.M. Boon;Daved H. Fremont
  • 通讯作者:
    Daved H. Fremont
136 Herpesvirus Entry Mediator and Cytomegalovirus ORF UL144 Bind a Common Region of B And T Lymphocyte Attenuator
  • DOI:
    10.1016/j.cyto.2007.07.141
  • 发表时间:
    2007-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    John R. Sedy;Christopher A. Nelson;Paula S. Norris;Kenneth M. Murphy;Chris A. Benedict;Daved H. Fremont;Carl F. Ware
  • 通讯作者:
    Carl F. Ware
Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice
  • DOI:
    10.1016/j.celrep.2019.01.052
  • 发表时间:
    2019-02-05
  • 期刊:
  • 影响因子:
  • 作者:
    Vanessa Salazar;Brett W. Jagger;Juthathip Mongkolsapaya;Katherine E. Burgomaster;Wanwisa Dejnirattisai;Emma S. Winkler;Estefania Fernandez;Christopher A. Nelson;Daved H. Fremont;Theodore C. Pierson;James E. Crowe;Gavin R. Screaton;Michael S. Diamond
  • 通讯作者:
    Michael S. Diamond
Toxoplasma Gondii Actin Assembles via Isodesmic Polymerization
  • DOI:
    10.1016/j.bpj.2012.11.3563
  • 发表时间:
    2013-01-29
  • 期刊:
  • 影响因子:
  • 作者:
    Kristen M. Skillman;Christopher Ma;Karthikeyan Diraviyam;Daved H. Fremont;John A. Cooper;L. David Sibley;David Sept
  • 通讯作者:
    David Sept

Daved H. Fremont的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daved H. Fremont', 18)}}的其他基金

Structure and Function of Proxvirus Immune Evasion Domains
Proxvirus 免疫逃避结构域的结构和功能
  • 批准号:
    9012755
  • 财政年份:
    2016
  • 资助金额:
    $ 32.76万
  • 项目类别:
Viral evasion of IFN function by decoy receptor sequestration
病毒通过诱饵受体隔离来逃避干扰素功能
  • 批准号:
    7672148
  • 财政年份:
    2009
  • 资助金额:
    $ 32.76万
  • 项目类别:
Immune Evasion Mechanisms of Ectromelia Virus
湿疣病毒的免疫逃避机制
  • 批准号:
    7641548
  • 财政年份:
    2008
  • 资助金额:
    $ 32.76万
  • 项目类别:
Subproject #7
子项目
  • 批准号:
    7099073
  • 财政年份:
    2005
  • 资助金额:
    $ 32.76万
  • 项目类别:
STRUCTURAL STUDIES OF IMMUNOLOGICAL PROCESSES
免疫过程的结构研究
  • 批准号:
    6978134
  • 财政年份:
    2004
  • 资助金额:
    $ 32.76万
  • 项目类别:
Viral Decoy Receptors
病毒诱饵受体
  • 批准号:
    6986782
  • 财政年份:
    2002
  • 资助金额:
    $ 32.76万
  • 项目类别:
Viral Decoy Receptors
病毒诱饵受体
  • 批准号:
    6829093
  • 财政年份:
    2002
  • 资助金额:
    $ 32.76万
  • 项目类别:
Viral Decoy Receptors
病毒诱饵受体
  • 批准号:
    6581065
  • 财政年份:
    2002
  • 资助金额:
    $ 32.76万
  • 项目类别:
Viral Decoy Receptors
病毒诱饵受体
  • 批准号:
    7152884
  • 财政年份:
    2002
  • 资助金额:
    $ 32.76万
  • 项目类别:
Viral Decoy Receptors
病毒诱饵受体
  • 批准号:
    6685869
  • 财政年份:
    2002
  • 资助金额:
    $ 32.76万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 32.76万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 32.76万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 32.76万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 32.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 32.76万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 32.76万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 32.76万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 32.76万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 32.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 32.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了